Literature DB >> 12079216

Micrographic surgery of basal cell carcinomas of the head.

Birgit Woerle1, Marc Heckmann, Birger Konz.   

Abstract

Basal cell carcinoma (BCC) is a locally invasive malignant cutaneous tumour with a rising incidence. This tumour can be treated successfully by a variety of techniques, including local excision, radiation, cryotherapy, curettage, electrodessication and laser obliteration. Micrographic surgery is a specialised type of minimal marginal surgery that offers higher cure rates than do other options in the treatment of contiguous skin cancers in selected settings. The horizontal frozen histological sections of the excised tumour permit complete microscopic examination of the surgical margin. Maximum sparing of tumour-free adjacent tissue is achieved with histological mapping of the tumour boundaries, and subsequent wound reconstruction is optimised. Data on topographical distribution, histopathological subtype, subclinical tumour extension, therapeutic procedures required for complete eradication, and recurrence rates were recorded in 3065 BCC of the head. Micrographic surgery is the treatment of choice for large or invasive primary BCC with uncertain clinical boundaries, especially in difficult anatomical regions, for recurrent or re-recurrent BCC, and for tumours with an aggressive histopathological pattern.

Entities:  

Mesh:

Year:  2002        PMID: 12079216     DOI: 10.1007/978-3-642-59410-6_25

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  3 in total

1.  [Secondary wound healing. Effective treatment concept after basal cell carcinoma resection in the central midface].

Authors:  T K Hoffmann; J Arnolds; P J Schuler; E Kultas; J Greve; N Mansour; M Bas; S Lang; A Hilpert
Journal:  HNO       Date:  2012-07       Impact factor: 1.284

2.  Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids.

Authors:  Verena Prokosch; Solon Thanos; Kristina Spaniol; Tobias Stupp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-10-01       Impact factor: 3.117

Review 3.  [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].

Authors:  C Kunte; B Konz
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.